Watch BDSX. Know when insiders buy.
One email the day a filing lands. Free.
BDSX
BIODESIX INC
26.63
+0.45 +1.72%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
62
WATCH · shorts 62
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $281MP/E —DIV YIELD —FCF YIELD -7.20%REV TTM $102.9M +34.5%NET INCOME −$27.8MNET DEBT $20M52W 5.46 – 30.60SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $26.9M | +34.2% | — | −$5.4M | −$7.3M | — | -0.71 | −$1.6M | $197K | −$1.8M | Aug 5 |
| Q1 2026 · Mar 31 | $25.6M | +42.3% | — | −$6.2M | −$7.8M | — | -0.81 | −$10.2M | $81K | −$10.2M | Aug 5 |
| Q4 2025 · Dec 31derived | $28.8M | +40.8% | — | −$2M | −$4M | — | -0.43 | $778K | $86K | $692K | Feb 26 |
| Q3 2025 · Sep 30 | $21.8M | +19.9% | — | −$7.1M | −$8.7M | — | -1.16 | −$8.9M | $48K | −$8.9M | Nov 3 |
| Q2 2025 · Jun 30 | $20M | +11.7% | — | −$9.7M | −$11.5M | — | -1.56 | −$6.6M | $51K | −$6.6M | Aug 5 |
| Q1 2025 · Mar 31 | $18M | +21.2% | — | −$9.1M | −$11.1M | — | -1.52 | −$8.6M | $74K | −$8.7M | Aug 5 |
| Q4 2024 · Dec 31derived | $20.4M | +39.3% | — | −$6.6M | −$8.3M | — | -1.03 | −$4.1M | $839K | −$4.9M | Feb 26 |
| Q3 2024 · Sep 30 | $18.2M | +34.5% | — | −$8.6M | −$10.3M | — | -1.40 | −$10.7M | $231K | −$10.9M | Nov 3 |
| Q2 2024 · Jun 30 | $17.9M | — | — | −$8.2M | −$10.8M | — | -0.08 | −$18.6M | $1.9M | −$20.5M | Nov 3 |
| Q1 2024 · Mar 31 | $14.8M | — | — | −$11M | −$13.6M | — | -0.14 | −$15.3M | $234K | −$15.5M | Nov 3 |
| Q4 2023 · Dec 31derived | $14.7M | — | — | −$6.9M | −$9.1M | — | -0.09 | −$12.3M | $3M | −$15.3M | Mar 3 |
| Q3 2023 · Sep 30 | $13.5M | — | — | −$7.2M | −$10.9M | — | -0.14 | −$3.8M | $5.8M | −$9.7M | Nov 1 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $88.5M | — | −$27.9M | −$35.3M | -39.8% | -4.67 | −$23.3M | $259K | −$23.5M | — | — |
| FY2024 · to Dec 31 | $71.3M | — | −$34.5M | −$42.9M | -60.2% | -6.64 | −$48.6M | $3.2M | −$51.9M | — | — |
| FY2023 · to Dec 31 | $49.1M | — | −$41.3M | −$52.1M | -106.2% | -0.64 | −$22.9M | $22.9M | −$45.8M | — | — |
| FY2022 · to Dec 31 | $38.2M | — | −$50.6M | −$65.4M | -171.3% | -1.55 | −$45M | $3.3M | −$48.3M | — | — |
| FY2021 · to Dec 31 | $54.5M | — | −$40.9M | −$43.2M | -79.2% | -1.58 | −$28.2M | $2.2M | −$30.5M | — | — |
| FY2020 · to Dec 31 | $45.6M | — | −$22.9M | −$65.4M | -143.7% | -6.48 | −$21.4M | $1.9M | −$23.3M | — | — |
Every number comes from BIODESIX INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.